Evidence map›Paper›PMID 35027509›Full record

ArticleGut and liver2022

Role of Serum Proteinase 3 Antineutrophil Cytoplasmic Antibodies in the Diagnosis, Evaluation of Disease Severity, and Clinical Course of Ulcerative Colitis.

So Imakiire, Hidetoshi Takedatsu, Keiichi Mitsuyama, Hideto Sakisaka, Kozo Tsuruta, Masaru Morita, Nobuaki Kuno, Koichi Abe, Sadahiro Funakoshi, Hideki Ishibashi and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Gut and liver, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Biomarkers in IBD: What to Utilize for the Diagnosis?Diagnostics (Basel, Switzerland) · 2023
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

So ImakiireDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-7076-4335
Hidetoshi TakedatsuDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-0318-0129
Keiichi MitsuyamaDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-5959-9607
Hideto SakisakaDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-6326-4789
Kozo TsurutaDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-6793-5762
Masaru MoritaDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-9652-2254
Nobuaki KunoDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0003-3665-2177
Koichi AbeDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-4507-5773
Sadahiro FunakoshiDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-4859-187X
Hideki IshibashiDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0003-3535-2906
Shinichiro YoshiokaDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-9068-1783
Takuji TorimuraDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-4863-4278
Fumihito HiraiDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-5493-5675
Fukuoka University · JPKurume University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsProteinase 3 antineutrophil cytoplasmic antibody (PR3-ANCA) is a serologic marker for granulomatosis with polyangiitis. However, recent studies have also shown their role as diagnostic markers for ulcerative colitis (UC). This study was performed to investigate the clinical roles of PR3-ANCAs in the disease severity, disease extension, and clinical course of UC.

methodsSerum PR3-ANCAs were measured in 173 UC patients including 77 patients with new-onset patients UC diagnosed within 1 month, 110 patients with Crohn's disease, 48 patients with other intestinal diseases, and 71 healthy controls. Associations between the PR3-ANCA titer and clinical data, such as disease severity, disease extension, and clinical course, were assessed. The clinical utility of PR3-ANCA measurement was evaluated by receiver operating characteristic (ROC) analysis.

resultsPR3-ANCA ≥3.5 U/mL demonstrated 44.5% sensitivity and 95.6% specificity for the diagnosis of UC in all patients. PR3-ANCA positivity was more prevalent in the 77 new-onset UC patients (58.4%). In this group, the disease severity and extension were more severe in PR3-ANCA positive patients than in PR3-ANCA negative group (p<0.001). After treatment, the partial Mayo scores were significantly decreased with the PR3-ANCA titers. The proportion of patients who required steroids for induction therapy was significantly higher among PR3-ANCA positive than negative group. ROC analysis revealed that PR3-ANCA ≥3.5 U/mL had 75% sensitivity and 69.0% specificity for steroid requirement in new-onset UC patients.

conclusionsOur results indicate that PR3-ANCA measurement is useful not only for diagnosing UC but also for evaluating disease severity and extension and predicting the clinical course.

Indexed as

Colitis, UlcerativeAntibodies, Antineutrophil CytoplasmicCase-Control StudiesCrohn DiseaseEnzyme-Linked Immunosorbent AssayHumansMyeloblastinSeverity of Illness IndexAntibodies, Antineutrophil CytoplasmicMyeloblastinClinical courseColitisDisease severityProteinase 3 antineutrophil cytoplasmic antibodyulcerative

Identifiers

PMID35027509
PMCPMC8761930
OpenAlexW4205787648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.